This multinational prospective noninferiority trial assesses whether biparametric magnetic resonance imaging (MRI) is noninferior to multiparametric MRI for diagnosis of clinically significant prostate cancer in biopsy-naive men with elevated prostate-specific antigen level and/or abnormal digital rectal examination findings.